Gunnar B. Kristensen
Position: Senior consultant, MD, PhD
Phone: +47 22 93 56 90
  • Born in Denmark 1946.
  • Medical Degree in 1972 from University of Århus, Denmark. 
  • Passed the American ECFMG examination in 1972.
  • Received basic clinical training in Denmark followed by specialization in gynecology and obstetrics. Received board certification in gynecology and obstetrics in 1982. 
  • I Worked at the University Hospital of Odense in Denmark from 1982 to 1989 with special interest in surgical gynecologic oncology. 
  • In 1989 I decided to work full time with gynecologic oncology and took a job at the Norwegian Radium Hospital where I have worked since as consultant.

Early in my carrier I was interested in genital infections and carried out several studies on this topic. Also I was interested in the development of precancer and cancer of the squamous epithelium of the female genital tract. This interest led to a more general interest for gynecological cancer.

I have had a steady scientific production of articles related to squamous cell neoplasia. I have published about diagnostic and treatment related aspects of cervical preinvasive and invasive neoplasia and a great number of articles related to HPV and cervical neoplasia. 

In recent years I have been working on studies on how to improve the efficacy of treatment for cervical cancer and at the same time reduce the morbidity from the treatment. These efforts have to a great extent been successful as evidenced by the increasing survival figures from our institution. As an example, I have introduced fertility saving surgery for early cervical cancer in Norway. Presently, we are running several studies to improve the detection of tumor spread outside the cervix at time of diagnosis, to predict prognosis and to predict the risk of late radiation damage after radiation for cervical cancer. In theses studies we are using themost modern techniques, such as PET scanning, dynamic MRI scanning and up-to-datelaboratory techniques with microarray technique, CGH and relevant protein analysis techniques.

I have been supervisor for several PhD students doing thesis work on both cervical cancer and ovarian cancer. The work on ovarian cancer has partly been clinical research and partly laboratory based biologic studies. 

Since 1998 I have been president of the Nordic Society for Gynecologic Oncology, which is acooperative group engaged in clinical research. The society partly runs protocols of its own and partly international protocols developed by other groups. In this period, the organization has developed into a professional, internationally recognized Clinical Trials Organization.

I am author of 145 scientific articles in peer-reviewed journals and of 19 chapters in books.
I am principal investigator in GOG ( the American Gynecologic Oncology Group) for the Nordic countries.

I am reviewer for the following scientific journals:
Lancet, Gynecologic Oncology, Acta Obstet Gynecol Scand, Cancer Letters, International Journal Gynecological Cancer, Critical Review in Oncology, Exper Review Anticancer, Molecular Diagnostics

I am member of the following scientific organizations: 
Nordic Society of Gynecologic Oncology, International Gynecological Cancer Society, American Society for Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer-Gynecological Cancer Cooperative Group, Scandinavisk Selskap for Gynekologi og Obstetrik, Norsk Forum for Gynekologisk Onkologi,


Author network for Gunnar Balle Kristensen by COREMINE medical

Publications 2017

Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland Å (2017)
Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
Dis Markers, 2017, 3098542
PubMed 28293063

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
PubMed 28118323

Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2017)
Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
Acta Oncol, 56 (5), 675-681
PubMed 28447564

Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I (2017)
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
Gynecol Oncol, 145 (3), 543-548
PubMed 28356187

Publications 2016

Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016)
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
Am J Clin Pathol, 145 (4), 449-58
PubMed 27149024

Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Clin Cancer Res, 22 (16), 4067-76
PubMed 27012812

Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
PLoS One, 11 (5), e0156259
PubMed 27244197

Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A (2016)
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Gynecol Oncol, 140 (3), 457-62
PubMed 26807488

Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Ann Oncol, 27 (8), 1505-10
PubMed 27407100

Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U, Hilpert F, Feyer P, Kristensen G, Hansen O, Keefe D, Herrstedt J (2016)
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
Lancet Oncol, 17 (4), 509-18
PubMed 26952945

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
PubMed 27488577

Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E, AURELIA Investigators (2016)
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecol Oncol, 144 (1), 65-71
PubMed 27871723

Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E (2016)
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
Ann Oncol, 27 (9), 1733-9
PubMed 27287207

Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC (2016)
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
Br J Cancer, 115 (2), 228-35
PubMed 27351218

Publications 2015

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO et al. (2015)
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Oncol, 17 (1), 78-89
PubMed 26590673

Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H (2015)
Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
Epigenetics, 10 (10), 970-80
PubMed 26291246

Lund KV, Simonsen TG, Hompland T, Kristensen GB, Rofstad EK (2015)
Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer
Radiother Oncol, 115 (3), 379-85
PubMed 25998804

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial investigators (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Lancet Oncol, 16 (8), 928-36
PubMed 26115797

Ruhlmann CH, Iversen TZ, Okera M, Muhic A, Kristensen G, Feyer P, Hansen O, Herrstedt J (2015)
Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy
Radiother Oncol, 117 (2), 333-7
PubMed 26372344

Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J (2015)
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
Eur J Cancer, 51 (7), 825-32
PubMed 25771433

Publications 2014

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014)
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma
Int. J. Gynecol. Cancer, 24 (9 3), S67-S72

Davidson B, Abeler VM, Forsund M, Holth A, Yang YQ, Kobayashi Y, Chen L, Kristensen GB, Shih LM, Wang TL (2014)
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
Hum. Pathol., 45 (4), 691-700

Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P (2014)
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mullerian Adenosarcoma of the Female Genital Tract
Int. J. Gynecol. Cancer, 24 (9 3), S78-S82

Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
Radiother Oncol, 113 (1), 132-8
PubMed 25443501

Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BMC Cancer, 14, 68
PubMed 24498853

Nielsen B, Hveem TS, Kildal W, Abeler VM, Kristensen GB, Albregtsen F, Danielsen HE (2014)
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
Cytometry A, 87 (4), 315-25
PubMed 25483227

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
J. Clin. Oncol., 32 (13), 1302-+

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W (2014)
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma
Int. J. Gynecol. Cancer, 24 (9 3), S83-S89

Wang Y, Herrstedt J, Havsteen H, Christensen RD, Mirza MR, Lund B, Maenpaa J, Kristensen G (2014)
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
BMC Cancer, 14, 937

Publications 2013

Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2013)
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
Radiother Oncol, 107 (1), 117-22
PubMed 23333024

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
PubMed 23372714

Greimel E, Kristensen GB, van der Burg MEL, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I, European Org Res Treatment Canc Gy NCIC Clinical Trials Grp (2013)
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
Gynecol. Oncol., 131 (2), 437-444

Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H (2013)
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
J Pathol, 230 (1), 59-69
PubMed 23335387

Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
Long-term outcomes after pelvic radiation for early-stage endometrial cancer
J Clin Oncol, 31 (31), 3951-6
PubMed 24019546

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian WD, Swart AM, Oza A, Perren T (2013)
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
Lancet Oncol., 14 (3), 236-243

Publications 2012

Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H (2012)
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
Cancer Res, 72 (20), 5285-95
PubMed 22890239

Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
PubMed 22531637

Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M (2012)
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
Ann Oncol, 24 (4), 937-43
PubMed 23104722

Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB (2012)
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-9
PubMed 22539562

Nielsen B, Albregtsen F, Kildal W, Abeler VM, Kristensen GB, Danielsen HE (2012)
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
Anal Cell Pathol (Amst), 35 (4), 305-14
PubMed 22596183

Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, Risberg BÅ (2012)
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
Virchows Arch, 461 (3), 291-8
PubMed 22824999

Tropé CG, Abeler VM, Kristensen GB (2012)
Diagnosis and treatment of sarcoma of the uterus. A review
Acta Oncol, 51 (6), 694-705
PubMed 22793037

Publications 2011

Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2011)
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
Int J Radiat Oncol Biol Phys, 82 (3), e485-92
PubMed 22014954

Andersen EK, Kristensen GB, Lyng H, Malinen E (2011)
Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers
Acta Oncol, 50 (6), 859-65
PubMed 21767185

Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
Radiother Oncol, 101 (1), 152-7
PubMed 21680035

Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
Clin Cancer Res, 17 (16), 5501-12
PubMed 21737508

Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD (2011)
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
PLoS One, 6 (4), e18064
PubMed 21533284

Kildal W, Micci F, Risberg B, Abeler VM, Kristensen GB, Heim S, Danielsen HE (2011)
Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
Mol Oncol, 6 (1), 98-107
PubMed 22062770

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian WD, Parmar MKB et al. (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
N. Engl. J. Med., 365 (26), 2484-2496

Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2011)
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
Ann Oncol, 23 (5), 1178-84
PubMed 21965471

Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Int. J. Gynecol. Cancer, 21 (2), 419-423

Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A (2011)
Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
Eur. J. Cancer, 47 3, S88-S92

Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg MEL, Reed NS, Verheijen RHM, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I (2011)
Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
Eur. J. Cancer, 47 (1), 57-64

Vistad I, Cvancarova M, Kristensen GB, Fosså SD (2011)
A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
J Cancer Surviv, 5 (2), 208-16
PubMed 21259075

Publications 2010

du Bois A, Herrstedt J, Hardy-Bessard AC, Muller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J (2010)
Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
J. Clin. Oncol., 28 (27), 4162-4169

Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G (2010)
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies
Eur. J. Cancer, 46 (13), 2422-2431

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
J. Clin. Oncol., 28 (20), 3323-3329

Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, MRC OV05, EORTC 55955 investigators (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Lancet, 376 (9747), 1155-63
PubMed 20888993

Tropé CG, Kristensen GB (2010)
The treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 72-90
PublikaID 106

Tropé CG, Kristensen GB (2010)
Surgery in treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 33-39
PublikaID 104

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010)
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
N Engl J Med, 363 (10), 943-53
PubMed 20818904

Publications 2009

Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009)
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients
Histopathology, 54 (3), 355-64
PubMed 19236512

Hellebust TP, Kristensen GB, Olsen DR (2009)
Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly
Int J Radiat Oncol Biol Phys, 76 (3), 713-8
PubMed 19427739

Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB, Lyng H (2009)
Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome
Oncol Rep, 22 (1), 11-5
PubMed 19513498

Kildal W, Abeler VM, Kristensen GB, Jenstad M, Thoresen SØ, Danielsen HE (2009)
The prognostic value of DNA ploidy in a total population of uterine sarcomas
Ann Oncol, 20 (6), 1037-41
PubMed 19201782

Kildal W, Pradhan M, Abeler VM, Kristensen GB, Danielsen HE (2009)
Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters
Eur J Cancer, 45 (13), 2412-7
PubMed 19622417

Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfør K, Glad IK, Kristensen GB, Lyng H (2009)
Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer
PLoS Genet, 5 (11), e1000719
PubMed 19911042

Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB (2009)
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
PLoS One, 4 (5), e5583
PubMed 19440550

Rud A, Bjorgo S, Kristensen GB, Kongsgaard UE (2009)
Hyperbaric oxygen therapy for late radiation tissue injury in gynaecological patients
Support. Care Cancer, 17 (12), 1517-1521

Vistad I, Kristensen GB, Fossa SD, Dahl AA, Morkrid L (2009)
Int. J. Radiat. Oncol. Biol. Phys., 73 (4), 1141-1147

Publications 2008

Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB (2008)
Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis
Int J Med Sci, 5 (3), 121-6
PubMed 18566674

Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, Lyng H (2008)
Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma
Open Virol J, 2, 74-81
PubMed 19440467

Lie AK, Kristensen G (2008)
Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma
Expert Rev. Mol. Diagn., 8 (4), 405-415

Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
Genome Biol, 9 (5), R86
PubMed 18500990

Vistad I, Cvancarova M, Fosså SD, Kristensen GB (2008)
Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
Int J Radiat Oncol Biol Phys, 71 (5), 1335-42
PubMed 18355976

Publications 2007

Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, Gribbestad IS (2007)
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
BMC Cancer, 7, 11
PubMed 17233882

Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT, Gynecologic Cancer Intergroup (2007)
Clinical trials in gynecological cancer
Int J Gynecol Cancer, 17 (3), 547-56
PubMed 17504371

Vistad I, Fosså SD, Kristensen GB, Dahl AA (2007)
Chronic fatigue and its correlates in long-term survivors of cervical cancer treated with radiotherapy
BJOG, 114 (9), 1150-8
PubMed 17655733

Vistad I, Fosså SD, Kristensen GB, Mykletun A, Dahl AA (2007)
The sexual activity questionnaire: pychometric properties and normative data in a norwegian population sample
J Womens Health (Larchmt), 16 (1), 139-48
PubMed 17324105

Wang Y, Kristensen GB, Børresen-Dale AL, Helland A (2007)
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
Ann Oncol, 18 (5), 964-6
PubMed 17488735

Publications 2006

Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H (2006)
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
BMC Clin Pharmacol, 6, 2
PubMed 16412237

Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
PLoS Med, 3 (3), e47
PubMed 16417408

Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
Clin Cancer Res, 12 (3 Pt 1), 791-9
PubMed 16467090

Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H (2006)
Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas
J Clin Microbiol, 44 (4), 1310-7
PubMed 16597856

Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfør K, Kristensen GB, Stokke T (2006)
Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
BMC Genomics, 7, 268
PubMed 17054779

Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM (2006)
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
Gynecol Oncol, 102 (1), 15-21
PubMed 16499955

Publications 2005

Benetkiewicz M, Wang Y, Schaner M, Wang P, Mantripragada KK, Buckley PG, Kristensen G, Børresen-Dale AL, Dumanski JP (2005)
High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
Genes Chromosomes Cancer, 42 (3), 228-37
PubMed 15578687

Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IeM (2005)
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Cancer Res, 65 (1), 331-7
PubMed 15665311

du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A et al. (2005)
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
Ann Oncol, 16 Suppl 8, viii7-viii12
PubMed 16239238

Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z (2005)
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
Gynecol Oncol, 99 (2), 278-86
PubMed 16061279

Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM, Danielsen HE (2005)
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients
Eur J Cancer, 41 (8), 1127-34
PubMed 15911235

Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A (2005)
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
PubMed 16229746

Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
PubMed 16042759

Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B (2005)
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
Cancer, 103 (11), 2313-9
PubMed 15844177

Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J et al. (2005)
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
Ann Oncol, 16 Suppl 8, viii36-viii38
PubMed 16239235

Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I, Gynecologic Cancer Intergroup, GOG, NCIC-CTG, AGO-OVAR, ANZGOG, JGOG, GINECO, SGCTG, MRC/NCRI et al. (2005)
Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
Ann Oncol, 16 Suppl 8, viii13-viii19
PubMed 16239232

Van de Putte G, Holm R, Lie AK, Baekelandt M, Kristensen GB (2005)
Markers of apoptosis in stage IB squamous cervical carcinoma
J Clin Pathol, 58 (6), 590-4
PubMed 15917408

Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB (2005)
Risk grouping in stage IB squamous cell cervical carcinoma
Gynecol Oncol, 99 (1), 106-12
PubMed 16137752

Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
PubMed 15712344

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
PubMed 16191507

Publications 2004

Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC (2004)
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
Cancer, 100 (10), 2139-47
PubMed 15139056

Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, Kristensen GB, Reich R, Kopolovic J (2004)
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
Clin Exp Metastasis, 21 (3), 191-9
PubMed 15387369

Kristensen G, Tropé C (2004)
Endometrial cancer: the management of high-risk disease
Curr Oncol Rep, 6 (6), 471-5
PubMed 15485617

Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, Kristensen GB, Sundfør K, Skjønsberg A, De Angelis PM (2004)
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
Int J Cancer, 111 (3), 358-66
PubMed 15221962

Micci F, Teixeira MR, Haugom L, Kristensen G, Abeler VM, Heim S (2004)
Genomic aberrations in carcinomas of the uterine corpus
Genes Chromosomes Cancer, 40 (3), 229-46
PubMed 15139002

Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R (2004)
E-cadherin and catenins in early squamous cervical carcinoma
Gynecol Oncol, 94 (2), 521-7
PubMed 15297198

Van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R (2004)
Cyclins and proliferation markers in early squamous cervical carcinoma
Gynecol Oncol, 92 (1), 40-6
PubMed 14751136

Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
PubMed 14760384

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
PubMed 15221786

Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z (2004)
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
Pathol Oncol Res, 10 (4), 212-8
PubMed 15619642

Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM (2004)
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma
Gynecol Oncol, 94 (2), 312-9
PubMed 15297167

Publications 2003

Alfsen GC, Reed W, Sandstad B, Kristensen GB, Abeler VM (2003)
The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma
Cancer, 98 (9), 1880-9
PubMed 14584070

Colombo N, du Bois A, Kristensen G, Ledermann J, Torri V, ICON4 Collaborators (2003)
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit - Reply
Lancet, 362 (9392), 1334

Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R (2003)
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
Clin Exp Metastasis, 20 (2), 161-9
PubMed 12705637

Givant-Horwitz V, Davidson B, van de Putte G, Dong HP, Goldberg I, Amir S, Kristensen GB, Reich R (2003)
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 599-609
PubMed 14669791

Kildal W, Kraggerud SM, Abeler VM, Heim S, Tropé CG, Kristensen GB, Risberg B, Lothe RA, Danielsen HE (2003)
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female
Hum Pathol, 34 (9), 946-9
PubMed 14562293

Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Tropé CG, Danielsen HE (2003)
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
Ann Oncol, 14 (10), 1494-500
PubMed 14504048

Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E (2003)
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
Int J Gynecol Cancer, 13 Suppl 2, 172-7
PubMed 14656276

Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH (2003)
X chromosome inactivation in cervical cancer patients
Cancer Genet Cytogenet, 146 (1), 73-6
PubMed 14499700

Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators (2003)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Lancet, 361 (9375), 2099-106
PubMed 12826431

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO et al. (2003)
Gene expression patterns in ovarian carcinomas
Mol Biol Cell, 14 (11), 4376-86
PubMed 12960427

van de Putte G, Holm R, Lie AK, Tropé CG, Kristensen GB (2003)
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
Gynecol Oncol, 89 (1), 140-7
PubMed 12694668

Publications 2002

Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R (2002)
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am J Clin Pathol, 117 (2), 225-34
PubMed 11863219

Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B, van de Putte G, Goldberg I (2002)
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
Clin Exp Metastasis, 19 (2), 135-44
PubMed 11964077

Publications 2001

Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM (2001)
Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix
Cancer, 92 (9), 2471-83
PubMed 11745305

Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB (2001)
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
J Clin Oncol, 19 (12), 2983-93
PubMed 11408493

Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ (2001)
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
J Clin Oncol, 19 (19), 3967-75
PubMed 11579118

Dai H, Holm R, Kristensen GB, Abeler VM, Børresen-Dale AL, Helland A (2001)
Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas
Anal Cell Pathol, 23 (2), 45-9
PubMed 11904459

Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R (2001)
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am J Clin Pathol, 115 (4), 517-24
PubMed 11293899

Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R (2001)
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin Cancer Res, 7 (11), 3457-64
PubMed 11705863

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM (2001)
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
Eur J Cancer, 37 (16), 2040-9
PubMed 11597382

Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
PubMed 11606079

Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, Kristensen GB, Bryne M, Reich R (2001)
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
Am J Surg Pathol, 25 (12), 1493-500
PubMed 11717538

Kristensen GB, Johannesen H, Aamand J (2001)
Mineralization of aged atrazine and mecoprop in soil and aquifer chalk
Chemosphere, 45 (6-7), 927-34
PubMed 11695615

Kristensen GB, Sørensen SR, Aamand J (2001)
Mineralization of 2,4-D, mecoprop, isoproturon and terbuthylazine in a chalk aquifer
Pest Manag Sci, 57 (6), 531-6
PubMed 11407030

Tropé C, Kristensen G, Kisic J, Kaern J (2001)
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
Eur J Gynaecol Oncol, 22 (3), 223-7
PubMed 11501778

Tropé C, Kristensen GB, Abeler VM (2001)
Clear-cell and papillary serous cancer: treatment options
Best Pract Res Clin Obstet Gynaecol, 15 (3), 433-46
PubMed 11476564

Publications 2000

Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM (2000)
Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990
Cancer, 89 (6), 1291-9
PubMed 11002225

Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
J Clin Oncol, 18 (22), 3775-81
PubMed 11078490

Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM (2000)
Carcinoma of the fallopian tube
Cancer, 89 (10), 2076-84
PubMed 11066048

Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
Anticancer Res, 20 (2B), 1061-7
PubMed 10810398

Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000)
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
Clin Exp Metastasis, 18 (2), 197-202
PubMed 11235996

Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V (2000)
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J Pathol, 192 (4), 460-9
PubMed 11113863

Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Tropé CG, Bryne M (2000)
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum Pathol, 31 (9), 1081-7
PubMed 11014575

Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA (2000)
Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival
Int J Cancer, 88 (2), 217-22
PubMed 11004671

Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C (2000)
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
PubMed 10684705

Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, Onsrud M, Pettersen E, Rosenberg P, Sandvei R, Sundfor K, Vergote I (2000)
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
Ann Oncol, 11 (3), 281-8
PubMed 10811493

Tropé CG, Kristensen G, Makar A (2000)
Surgery for borderline tumor of the ovary
Semin Surg Oncol, 19 (1), 69-75
PubMed 10883027

Publications 1999

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer
Ann Oncol, 10 (11), 1335-41
PubMed 10631462

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study
Clin Cancer Res, 5 (10), 2848-53
PubMed 10537352

Baekelandt M, Kristensen GB, Nesland JM, Tropé CG, Holm R (1999)
Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer
J Clin Oncol, 17 (7), 2061
PubMed 10561259

Baekelandt M, Kristensen GB, Tropé CG, Nesland JM, Holm R (1999)
Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer
Anticancer Res, 19 (5C), 4469-74
PubMed 10650794

Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjamer A, Berner A (1999)
Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies - Evaluation of five epithelial markers
Virchows Arch. Int. J. Pathol., 435 (1), 43-49

Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P (1999)
Prospectively detected cancer in familial breast/ovarian cancer screening
Acta Obstet Gynecol Scand, 78 (10), 906-11
PubMed 10577622

Skomedal H, Helland A, Kristensen GB, Holm R, Børresen-Dale AL (1999)
Allelic imbalance at chromosome region 11q23 in cervical carcinomas
Eur J Cancer, 35 (4), 659-63
PubMed 10492643

Skomedal H, Kristensen GB, Lie AK, Holm R (1999)
Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas
Gynecol Oncol, 73 (2), 223-8
PubMed 10329038

Skomedal H, Kristensen GB, Nesland JM, Børresen-Dale AL, Tropé C, Holm R (1999)
TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus
J Pathol, 187 (5), 556-62
PubMed 10398121

Publications 1998

Bryne M, Boysen M, Alfsen CG, Abeler VM, Sudbø J, Nesland JM, Kristensen GB, Piffko J, Bankfalvi A (1998)
The invasive front of carcinomas. The most important area for tumour prognosis?
Anticancer Res, 18 (6B), 4757-64
PubMed 9891553

Helland A, Karlsen F, Due EU, Holm R, Kristensen G, Børresen-Dale Al (1998)
Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load
Br J Cancer, 78 (1), 69-72
PubMed 9662253

Hofstra LS, Kristensen GB, Willemse PH, Vindevoghel A, Meden H, Lahousen M, Oberling F, Sorbe B, Crump M, Sklenar I, Sluiter WJ, Kiese B, Trope CG, de Vries EG (1998)
Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma
J Clin Oncol, 16 (10), 3335-44
PubMed 9779710

Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B, Johansson B (1998)
Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis
Int J Gynecol Pathol, 17 (2), 146-53
PubMed 9553812

Marth C, Tropé C, Vergote IB, Kristensen GB (1998)
Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer
Eur J Cancer, 34 (8), 1175-80
PubMed 9849475

Nordal RR, Kristensen GB, Stenwig AE, Tropé CG, Nesland JM (1998)
Immunohistochemical analysis of p53 protein in uterine sarcomas
Gynecol Oncol, 70 (1), 45-8
PubMed 9698472

Schulerud H, Kristensen GB, Liestøl K, Vlatkovic L, Reith A, Albregtsen F, Danielsen HE (1998)
A review of caveats in statistical nuclear image analysis
Anal Cell Pathol, 16 (2), 63-82
PubMed 9692681

Publications 1997

Helland A, Børresen-Dale AL, Peltomäki P, Hektoen M, Kristensen GB, Nesland JM, de la Chapelle A, Lothe RA (1997)
Microsatellite instability in cervical and endometrial carcinomas
Int J Cancer, 70 (5), 499-501
PubMed 9052745

Kristensen GB, Tropé C (1997)
Epithelial ovarian carcinoma
Lancet, 349 (9045), 113-7
PubMed 8996432

Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG (1997)
An evaluation of prognostic factors in uterine carcinosarcoma
Gynecol Oncol, 67 (3), 316-21
PubMed 9441781

Skomedal H, Kristensen GB, Abeler VM, Børresen-Dale AL, Tropé C, Holm R (1997)
TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas
J Pathol, 181 (2), 158-65
PubMed 9120719

Tropé C, Kaern J, Kristensen G, Rosenberg P, Sorbe B (1997)
Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer
Ann Oncol, 8 (8), 803-6
PubMed 9332691

Tropé C, Kristensen G (1997)
Current status of chemotherapy in gynecologic cancer
Semin Oncol, 24 (5 Suppl 15), S15-1-S15-22
PubMed 9346216

Trope C, Kristensen G (1997)
Current status of chemotherapy in gynecologic cancer
Semin. Oncol., 24 (5 15), 1-22

Publications 1996

Dørum A, Kristensen GB, Abeler VM, Tropé CG, Møller P (1996)
Early detection of familial ovarian cancer
Eur J Cancer, 32A (10), 1645-51
PubMed 8983269

Kaern J, Tropé C, Sundfoer K, Kristensen GB (1996)
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Gynecol Oncol, 60 (3), 387-92
PubMed 8774643

Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B, Hagmar B (1996)
Use of multiple PCR primer sets for optimal detection of human papillomavirus
J Clin Microbiol, 34 (9), 2095-100
PubMed 8862564

Kristensen GB, Holm R, Abeler VM, Tropé CG (1996)
Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study
Cancer, 78 (3), 433-40
PubMed 8697388

Kristensen GB, Holm R, Abeler VM, Tropé CG (1996)
Evaluation of the prognostic significance of nm23/NDP kinase protein expression in cervical carcinoma: an immunohistochemical study
Gynecol Oncol, 61 (3), 378-83
PubMed 8641619

Kristensen GB, Karlsen F, Jenkins A, Kaern J, Abeler VM, Tropé CG (1996)
Human papilloma virus has no prognostic significance in cervical carcinoma
Eur J Cancer, 32A (8), 1349-53
PubMed 8869098

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG (1996)
The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma
Gynecol Oncol, 62 (2), 254-9
PubMed 8751558

Scheistrøen M, Tropé C, Kaern J, Abeler VM, Pettersen EO, Kristensen GB (1996)
Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment
Gynecol Oncol, 61 (2), 253-8
PubMed 8626143

Trope C, Sundfor K, Kristensen G, Iversen T (1996)
Surgical treatment for cervical cancer and presentation of the genito urinary function

Trope C, Sundfor K, Kristensen G, Iversen T (1996)
Standard and new approaches in surgery

Publications 1995

Hagmar B, Christensen JJ, Johansson B, Kalantari M, Ryd W, Skyldberg B, Walaas L, Wärleby B, Kristensen GB (1995)
Implications of human papillomavirus type for survival in cervical squamous cell carcinoma
Int J Gynecol Cancer, 5 (5), 341-345
PubMed 11578501

Karlsen F, Kristensen G, Holm R, Chitemerere M, Berner A, Hagmar BM (1995)
High incidence of human papillomavirus in 146 cervical carcinomas. A study using three different pairs of consensus primers, and detecting viral genomes with putative deletions
Eur J Cancer, 31A (9), 1511-6
PubMed 7577081

Kristensen GB, Baekelandt M, Vergote IB, Tropé C (1995)
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma
Eur J Cancer, 31A (11), 1778-80
PubMed 8541099

Kristensen GB, Kaern J, Abeler VM, Hagmar B, Tropé CG, Pettersen EO (1995)
No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients
Gynecol Oncol, 57 (1), 79-85
PubMed 7705705

Makar AP, Baekelandt M, Tropé CG, Kristensen GB (1995)
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer
Gynecol Oncol, 56 (2), 175-80
PubMed 7896181

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG (1995)
The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma
Acta Oncol, 34 (6), 797-802
PubMed 7576748

Scheistrøen M, Tropé C, Koern J, Pettersen EO, Abeler VM, Kristensen GB (1995)
Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75 patients
Cancer, 75 (1), 72-80
PubMed 7804980

Skomedal H, Kristensen G, Helland A, Nesland JM, Kooi S, Børresen AL, Holm R (1995)
TP53 gene mutations and protein accumulation in primary vaginal carcinomas
Br J Cancer, 72 (1), 129-33
PubMed 7599041

Skomedal H, Kristensen G, Holm R (1995)
Expression of retinoblastoma tumor suppressor gene protein, epidermal growth factor receptor, and c-erbB-2 oncoprotein in primary vaginal carcinomas
Gynecol Oncol, 59 (3), 379-83
PubMed 8522259

Tropé C, Kristensen G (1995)
[Preoperative identification of malignancy among women with a pelvic mass]
Tidsskr Nor Laegeforen, 115 (7), 812-3
PubMed 7701484

Publications 1994

Dørum A, Kristensen GB, Tropé C (1994)
A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma
Eur J Cancer, 30A (10), 1470-4
PubMed 7833104

Helland A, Børresen AL, Kristensen G, Rønningen KS (1994)
DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis
Cancer Epidemiol Biomarkers Prev, 3 (6), 479-86
PubMed 8000298

Kaern J, Tropé CG, Kristensen GB, Pettersen EO (1994)
Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma
Cancer, 73 (7), 1870-7
PubMed 8137213

Kaern J, Tropé CG, Kristensen GB, Tveit KM, Pettersen EO (1994)
Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study
Am J Obstet Gynecol, 170 (2), 479-87
PubMed 8116701

Kristiansen E, Jenkins A, Kristensen G, Ask E, Kaern J, Abeler V, Lindqvist BH, Tropé C, Kristiansen BE (1994)
Human papillomavirus infection in Norwegian women with cervical cancer
APMIS, 102 (2), 122-8
PubMed 8167008

Makar AP, Holm R, Kristensen GB, Nesland JM, Tropé CG (1994)
The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
Int J Gynecol Cancer, 4 (3), 194-199
PubMed 11578406

Publications 1993

Dørum A, Kristensen GB, Langebrekke A, Sørnes T, Skaar O (1993)
Evaluation of endometrial thickness measured by endovaginal ultrasound in women with postmenopausal bleeding
Acta Obstet Gynecol Scand, 72 (2), 116-9
PubMed 8383406

Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Børresen AL (1993)
Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
J Pathol, 171 (2), 105-14
PubMed 8283348

Holm R, Skomedal H, Helland A, Kristensen G, Børresen AL, Nesland JM (1993)
Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri
J Pathol, 169 (1), 21-6
PubMed 8433212

Kaern J, Tropé CG, Kristensen GB, Abeler VM, Pettersen EO (1993)
DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary
Int J Gynecol Cancer, 3 (6), 349-358
PubMed 11578368

Acta Obstet. Gynecol. Scand., 72 (8), 687

Makar AP, Kaern J, Kristensen GB, Vergote I, Børmer OP, Tropé CG (1993)
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
Int J Gynecol Cancer, 3 (5), 299-303
PubMed 11578361

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1993)
Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Gynecol Oncol, 49 (1), 3-7
PubMed 8482556

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1993)
Serum CA 125 level allows early identification of nonresponders during induction chemotherapy
Gynecol Oncol, 49 (1), 73-9
PubMed 8482563

Makar AP, Kristensen GB, Nesland J, Børmer OP, Tropé CG (1993)
Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies
Int J Gynecol Cancer, 3 (2), 116-121
PubMed 11578331

Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V (1993)
Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors
Gynecol Oncol, 51 (2), 236-43
PubMed 8276300

Publications 1992

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1992)
CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
Gynecol Oncol, 45 (3), 323-8
PubMed 1612511

Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG (1992)
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis
Obstet Gynecol, 79 (6), 1002-10
PubMed 1579296

Publications 1990

Kristensen GB, Beiter EC, Mather O (1990)
Acta Obstet. Gynecol. Scand., 69 (6), 497-500